Regeneron's Pozelimab and Cemdisiran Combination Study for Paroxysmal Nocturnal Hemoglobinuria: A Potential Breakthrough Treatment.

Regeneron Pharmaceuticals is conducting a study to assess the long-term safety and effectiveness of a combination of pozelimab and cemdisiran in treating paroxysmal nocturnal hemoglobinuria (PNH). The study follows a non-randomized, parallel assignment model and began on March 7, 2023. Successful results could enhance Regeneron's market position in the pharmaceutical industry and impact its stock performance.

Regeneron Pharmaceuticals ((REGN)) has recently announced an update on its ongoing clinical study, titled 'An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria.' This study, which began on March 7, 2023, aims to assess the long-term safety and effectiveness of the pozelimab and cemdisiran combination in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder [1].

The study follows a non-randomized, parallel assignment model without masking, focusing on treatment as the primary purpose. This design allows researchers to observe the effects of the drug combination directly and assess its potential benefits and risks. The last update was submitted on August 18, 2025, with the primary completion date yet to be announced [1].

The intervention involves two experimental drugs, pozelimab and cemdisiran, which are being tested for their ability to manage PNH symptoms and improve patient outcomes. These drugs are intended to work together to provide a more effective treatment option for those affected by PNH. The study's progress and anticipated milestones are crucial for tracking its development.

The clinical update could significantly influence Regeneron's stock performance and investor sentiment. Successful results may enhance the company's market position in the pharmaceutical industry and attract competitive attention. Competitors in the PNH treatment space will be closely monitoring these developments, as they could shift market dynamics [1].

Regeneron Pharmaceuticals reported $12.89 EPS for its most recent quarter, exceeding the consensus estimate of $8.43, with revenues of $3.68 billion. The company declared a quarterly dividend of $0.88 per share, representing a 0.6% yield, with a dividend payout ratio of 8.87% [2]. Institutional investors and hedge funds own 83.31% of the company's stock, with several funds adjusting their positions recently [2].

The study is ongoing, with further details available on the ClinicalTrials portal. Investors and financial professionals should closely monitor the progress and results of this study, as they may have a significant impact on Regeneron Pharmaceuticals' stock performance and market position.

References:
[1] https://www.tipranks.com/news/company-announcements/regenerons-promising-pnh-treatment-study-a-potential-game-changer
[2] https://www.marketbeat.com/instant-alerts/filing-regeneron-pharmaceuticals-inc-nasdaqregn-shares-sold-by-ethic-inc-2025-08-17/